Wegovy Sulfur Burps

1. What sulfur burps actually are

Sulfur burps — also called “rotten-egg burps” in patient communities — are eructations that carry the unmistakable odor of hydrogen sulfide gas (H2S). The chemical signature is identical to the smell of rotten eggs, sewage gas, or geothermal hot springs, because all three involve the same compound: H2S released by sulfur-reducing bacteria.

In healthy adults outside of GLP-1 therapy, sulfur burps are typically triggered by high-sulfur food binges (eggs, red meat, garlic, cruciferous vegetables), gastric infections like Helicobacter pylori, small intestinal bacterial overgrowth (SIBO), or delayed gastric emptying from other causes (diabetes, post-surgical states). The common thread: food that contains sulfur amino acids (cysteine, methionine) sits in the gut long enough for sulfur-reducing bacteria to break it down anaerobically, releasing H2S.

On Wegovy, sulfur burps are a downstream consequence of the medication's intended pharmacologic action — delayed gastric emptying — rather than a hypersensitivity or allergic reaction. They are not, in isolation, a sign that something is wrong with the medication or with you.

2. The Wegovy mechanism: why semaglutide produces them

Semaglutide (the active molecule in Wegovy) is a GLP-1 receptor agonist. One of its core mechanisms — and a major driver of both its weight-loss benefits and its GI side effects — is delayed gastric emptying. Clinical studies have measured gastric residence time on semaglutide at 30-70% longer than baseline, with peak delay occurring 24-72 hours after each weekly injection at therapeutic doses.

The downstream chain of events that produces sulfur burps:

1. Food enters the stomach and begins normal digestion.
2. Gastric emptying is slowed by semaglutide's action on GLP-1 receptors in the gastric pacemaker cells and vagal afferents.
3. Sulfur-containing amino acids (cysteine, methionine) and sulfur compounds in food sit longer than usual in the upper GI tract.
4. Anaerobic bacteria in the stomach and proximal small intestine ferment these compounds, producing hydrogen sulfide as a byproduct.
5. H2S gas accumulates and is eventually expelled retrograde through the esophagus as a burp, carrying the rotten-egg odor.

The mechanism is the same one that produces sulfur burps in non-GLP-1 contexts like gastroparesis or post-bariatric surgery — extended food residence in the upper GI plus the right substrate plus the right bacteria. Wegovy just creates that combination more reliably during titration.

3. How often they happen on Wegovy

The Wegovy FDA prescribing label, drawing from the STEP-1 and STEP-2 clinical trials, lists eructation in approximately 7% of patientsat the 2.4mg maintenance dose, compared to ~1% on placebo. “Eructation” in trial reporting includes both odorless and odorous burps; the sulfur-specific subset is not separately quantified in the label.

Patient surveys and post-marketing reports suggest sulfur-specific burps affect roughly 5-10% of Wegovy users at some point during titration. The frequency varies by:

• Dose phase: Higher during weeks 1-4 (initial 0.25mg) and around each dose escalation, especially the jumps to 1.0mg (week 9) and 1.7mg (week 13).
• Diet: Higher in patients with sulfur-rich diets (heavy red meat, eggs, garlic, onions, broccoli, cauliflower, dairy).
• Hydration: Worse in dehydrated patients — water dilutes substrate concentration and supports normal motility.
• Baseline GI status: Patients with pre-existing GERD, gastroparesis, or H. pylori carriage are more susceptible.

4. When they typically start and how long they last

Most patients who experience sulfur burps notice them within the first 1-4 weeks of starting Wegovy, or within 1-2 weeks of any dose escalation. The 24-72-hour window after each weekly injection is the most common flare period, coinciding with peak semaglutide plasma concentrations and peak gastric-emptying delay.

Duration patterns typically observed in clinical practice:

• Acute flare: 1-3 days per week, usually 24-72 hours after injection.
• Titration window: More frequent during weeks 1-4 and during each dose-escalation step.
• Stable maintenance: Frequency typically drops substantially by weeks 8-12 of stable dosing as the gut adapts.
• Persistent cases: Sulfur burps continuing beyond 3 months at a stable dose warrant prescriber evaluation to rule out H. pylori, SIBO, gallbladder dysfunction, or gastroparesis exacerbation.

5. Self-management strategies that work

No specific medication has been validated through controlled trials for GLP-1-induced sulfur burps. The interventions below are drawn from gastroenterology consensus for managing delayed gastric emptying and from patient-reported experience on Wegovy and Zepbound. Discuss any new supplement or OTC medication with your prescriber before starting.

Eating pattern modifications

• Smaller, more frequent meals: 4-6 small meals daily rather than 2-3 large ones — reduces gastric load and substrate available for fermentation.
• Stay upright 60-90 minutes after eating: Gravity assists gastric emptying and reduces retrograde gas movement up the esophagus.
• Stop eating 3 hours before bed: Overnight gastric stasis amplifies fermentation; an empty stomach overnight reduces morning sulfur burps.

Dietary substrate reduction

• Reduce high-sulfur foods during flare windows: red meat, eggs, garlic, onions, leeks, asparagus, cruciferous vegetables (broccoli, cauliflower, Brussels sprouts, cabbage), dairy.
• Short low-FODMAP trial (1-2 weeks): If reduced-sulfur eating alone doesn't help, a structured low-FODMAP trial may identify additional fermentable triggers. Work with a registered dietitian if possible.
• Avoid alcohol on injection days — alcohol delays gastric emptying further and amplifies GI symptoms.

Hydration and adjuncts

• Water intake 2-3L daily: Dilutes substrate, supports motility, reduces constipation that worsens overall GI symptoms.
• Ginger tea or capsules: Long-standing evidence base for prokinetic effect and nausea reduction; well-tolerated.
• Peppermint tea: May relax lower esophageal sphincter (caution if you have GERD) but reduces upper GI gas sensations for some patients.
• Probiotic trial (4-6 weeks): Strain-specific evidence is limited, but some patients report improvement with multi-strain probiotic supplementation. Discuss with your prescriber.

Over-the-counter options

• Simethicone (e.g., Gas-X): Reduces surface tension of gas bubbles in the gut; minimal systemic absorption; generally safe short-term.
• Bismuth subsalicylate (e.g., Pepto-Bismol): Binds H2S and reduces sulfur odor specifically; safe short-term but avoid daily long-term use due to salicylate accumulation risk.
• Activated charcoal: Some anecdotal benefit; can interfere with absorption of other medications — separate dosing by 2+ hours.

GLP1Zoom does not prescribe medications or recommend doses. If any of these self-management measures don't resolve symptoms within 1-2 weeks, escalate to your prescriber rather than continuing to layer OTC products indefinitely.

6. When to call your prescriber

Isolated sulfur burps without other symptoms are generally benign and self-limiting. Contact your prescriber promptly if sulfur burps occur alongside any of the following:

• Severe abdominal pain, particularly upper abdominal pain radiating to the back — possible pancreatitis warning (rare but serious GLP-1 risk).
• Persistent vomiting preventing fluid retention for more than 24 hours — dehydration risk.
• Fever with GI symptoms — possible gastroenteritis or other infection requiring evaluation.
• Blood in vomit or stool (bright red or black/tarry) — requires same-day medical evaluation.
• Yellowing of skin or eyes (jaundice), right-upper-quadrant pain — possible gallbladder dysfunction, a known GLP-1 association.
• Severe bloating with inability to pass gas or stool — possible bowel obstruction.
• Unexplained weight loss beyond what your Wegovy trajectory predicts, plus persistent GI symptoms — warrants workup.
• Sulfur burps persisting more than 3 months at a stable dose despite self-management — may warrant H. pylori, SIBO, or gastroparesis evaluation.

The decision to continue, pause, dose-reduce, or discontinue Wegovy belongs to you and your prescriber. GLP1Zoom is an educational and comparison resource — we do not provide medical advice or recommend specific clinical actions.

7. Sulfur burps on other GLP-1s

Delayed gastric emptying is a class effect of GLP-1 receptor agonists, so sulfur burps can occur on any of them. Reported eructation rates from FDA labels:

• Wegovy (semaglutide 2.4mg): ~7% eructation rate.
• Ozempic (semaglutide up to 2.0mg): ~7% eructation rate.
• Zepbound (tirzepatide up to 15mg): ~6% eructation rate.
• Mounjaro (tirzepatide up to 15mg): ~6% eructation rate.
• Saxenda (liraglutide 3.0mg): ~4% eructation rate.
• Rybelsus (oral semaglutide): ~5% eructation rate.

Practical implication: switching GLP-1s specifically to escape sulfur burps is rarely successful. The class-effect mechanism dominates. Some patients report subjective improvement on tirzepatide-based drugs (Zepbound, Mounjaro), possibly related to the dual GIP/GLP-1 mechanism producing slightly less aggressive gastric-emptying delay, but the difference is small. Any drug switch should be a prescriber-led decision driven by overall tolerability, not isolated sulfur burps.

8. What changes as titration proceeds

For most patients, sulfur-burp frequency follows a predictable trajectory across the standard 16-week Wegovy titration:

• Weeks 1-4 (0.25mg): First exposure; sulfur burps possible but often mild. Many patients have no symptoms at this dose.
• Weeks 5-8 (0.5mg): First escalation; new flare window. Symptoms often resemble or slightly exceed week 1-4 intensity.
• Weeks 9-12 (1.0mg): Major escalation. This is the dose where many patients first feel the medication's GI effects, including sulfur burps if they hadn't before.
• Weeks 13-16 (1.7mg): Another flare window during transition. After 2-3 weeks at 1.7mg, gut adaptation typically reduces frequency.
• Maintenance (2.4mg, week 17+): Peak dose reached. Initial 1-2 weeks may bring renewed symptoms; thereafter, most patients see frequency drop substantially.

Across the full titration, patients who proactively manage sulfur burps with the dietary and lifestyle strategies above generally report decreasing frequency by maintenance. Patients who don't adapt their eating patterns often continue to experience them intermittently. The medication itself doesn't change — the gut and the diet do.

9. Frequently asked questions

Why does Wegovy cause sulfur burps?

Wegovy (semaglutide) slows gastric emptying by acting on GLP-1 receptors — food sits in the stomach 30-70% longer than baseline. The extended residence time allows gut bacteria to ferment sulfur-containing amino acids (cysteine, methionine) in protein-rich foods, producing hydrogen sulfide gas (H2S). When H2S rises back up the esophagus, it carries the characteristic rotten-egg odor. This is the same mechanism behind sulfur burps from non-GLP-1 causes like H. pylori infection or excess sulfur-rich food intake, just amplified by slower transit.

How common are sulfur burps on Wegovy?

The Wegovy FDA prescribing label lists eructation (medical term for burping) in approximately 7% of patients during STEP-1 clinical trials, versus ~1% on placebo. Sulfur-specific burps are a subset — anecdotal reports and patient surveys suggest roughly 5-10% of Wegovy users experience the rotten-egg variant during titration. Frequency typically peaks during dose-escalation weeks (especially weeks 5-9 transitioning to 0.5mg and 1.0mg) and diminishes once steady-state tolerance is established.

When do sulfur burps typically start on Wegovy?

Most patients who experience sulfur burps notice them within the first 1-4 weeks of starting Wegovy or within 1-2 weeks of any dose escalation. They tend to cluster 24-72 hours after each weekly injection — coinciding with peak semaglutide plasma concentrations and peak gastric-emptying delay. By week 8-12 of stable dosing, frequency usually drops as the gut adapts. Persistent sulfur burps beyond 3 months at a stable dose warrant prescriber discussion to rule out other contributors (H. pylori, SIBO, gallbladder dysfunction).

How do I stop sulfur burps from Wegovy?

No medication has been validated specifically for GLP-1-induced sulfur burps. Patient-reported tactics with the strongest mechanistic plausibility include: smaller meals (4-6 daily rather than 3 large), reducing high-sulfur foods (red meat, eggs, garlic, onions, cruciferous vegetables, dairy) during flare weeks, staying upright 60-90 minutes after eating, increased water intake, ginger or peppermint tea, and a short low-FODMAP trial. Over-the-counter simethicone or bismuth subsalicylate may provide symptomatic relief. Discuss any persistent OTC use with your prescriber.

When should I worry about sulfur burps on Wegovy?

Isolated sulfur burps without other symptoms are generally benign and self-limiting. Contact your prescriber if burps are accompanied by severe abdominal pain (especially radiating to the back, which can signal pancreatitis), persistent vomiting preventing fluid retention, fever, blood in vomit or stool, unexplained weight loss beyond what your Wegovy trajectory predicts, or yellowing of skin/eyes (jaundice — gallbladder warning). Sulfur burps plus these red-flag symptoms can indicate gastroparesis complications, gallbladder disease, or other GI pathology requiring evaluation.

Do sulfur burps happen on Zepbound or Ozempic too?

Yes. All GLP-1 receptor agonists slow gastric emptying and can produce sulfur burps via the same mechanism. Reported eructation rates: Ozempic (semaglutide) ~7%, Wegovy (semaglutide) ~7%, Zepbound (tirzepatide) ~6%, Mounjaro (tirzepatide) ~6%, Saxenda (liraglutide) ~4%. Tirzepatide-based drugs (Zepbound, Mounjaro) may produce slightly fewer GI symptoms overall due to dual GIP/GLP-1 mechanism, but sulfur burps remain a possibility on any GLP-1. Switching drugs to escape sulfur burps is not typically effective — class effect dominates.

• Editorial board reviewed
• CC BY 4.0 data
• FDA-source citations
• Affiliate disclosed

This guide is educational and does not constitute medical advice. GLP1Zoom does not prescribe medications or recommend specific doses — all clinical decisions should be made in consultation with your prescriber. Affiliate-disclosed. Full disclaimer.